July 2026
LSD
What July 2026's 4 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 3 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research published in July 2026 on LSD was limited to a review and an in silico toxicology study; no new clinical trial data on LSD itself were reported. The review suggests LSD has therapeutic potential for conditions like generalized anxiety disorder, while the in silico study indicates that LSD derivatives may have concerning toxicological profiles, particularly for cardiopulmonary and genotoxic endpoints. However, these findings are preliminary and based on computational predictions, not human data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study. All 4 matching studies were reviewed; the 3 that directly address the question are shown here.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic-Assisted Psychosexual Therapy 2026 | review | Supports | Argues that classic psychedelics including LSD can enable direct engagement with traumatic antecedents of sexual difficulties by altering consciousness and softening defensive avoidance. | |
| Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule? 2026 | review | Supports | Argues that psychedelics including LSD show therapeutic potential for mental health conditions and that there are paths for rescheduling them from Schedule I to reduce research barriers. | |
| The toxicity of psychedelic LSD derivatives: 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), 1-butyryl-LSD (1B-LSD), 1-valeryl-LSD (1V-LSD) and 1-cyclopropylmethanoyl-LSD (1cP-LSD)-prediction of toxicological parameters relevant to clinical and forensic toxicology using multi-in silico approach. 2026 | in silico toxicological assessment | Mixed | Predicted that LSD derivatives have varying toxicity profiles, with elevated pulmonary risk for some, genotoxicity alerts for others, and strong hERG inhibition for 1V-LSD, suggesting potential proarrhythmic risk. |
Argues that classic psychedelics including LSD can enable direct engagement with traumatic antecedents of sexual difficulties by altering consciousness and softening defensive avoidance.
review
Argues that psychedelics including LSD show therapeutic potential for mental health conditions and that there are paths for rescheduling them from Schedule I to reduce research barriers.
review
Predicted that LSD derivatives have varying toxicity profiles, with elevated pulmonary risk for some, genotoxicity alerts for others, and strong hERG inhibition for 1V-LSD, suggesting potential proarrhythmic risk.
in silico toxicological assessment
Points of agreement
- LSD and its derivatives are considered to have therapeutic potential for mental health conditions.
- There is interest in reducing regulatory barriers to LSD research and medical use.
Conflicts
- The therapeutic potential of LSD is contrasted by the predicted toxicological risks of its derivatives, though these are different compounds.
Gaps
- No new clinical trial data on LSD itself were reported in July 2026.
- The toxicological predictions are in silico and require empirical validation.
- Long-term safety and efficacy of LSD in clinical populations remain unstudied in this set.